Paclitaxel- and platinum-based chemotherapy
PreclinicalSmall molecule
Paclitaxel- and platinum-based chemotherapy is one of 47 small molecule programs targeting Esophageal Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Esophageal Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Eloxatin
TevaPhase 3
Adrucil
EElorac, Inc.
Approved
Taxotere
AAvyxa
Approved
Lenvima
EisaiPhase 3
Tecentriq
RochePhase 3
Lobaplatin
SSun Yat-sen University
Approved
Fusilev
DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHenan Cancer Hospital